Sakamoto Takuro, Fujimoto Naohiro, Nakashima Michitaka
Department of Urology, Hospital of the University of Occupational and Environmental Health.
Kyushu Rosai Hospital.
Nihon Hinyokika Gakkai Zasshi. 2021;112(4):220-223. doi: 10.5980/jpnjurol.112.220.
A 78-year-old man was referred to our institution for the evaluation of macroscopic hematuria and a bladder tumor for which we initially performed a transurethral resection of the bladder tumor. Pathological examination revealed that the tumor was a high-grade invasive urothelial carcinoma that was at least stage T2. Computed tomography scan showed a bladder carcinoma with no nodal or distant metastases. Assuming radical cystectomy, we administered two courses of neoadjuvant chemotherapy (i.e., gemcitabine and cisplatin chemotherapy). Unfortunately, the bladder tumor metastasized to the right internal iliac lymph node. We performed consolidative radiotherapy (54 Gy/ 27 fractions to the bladder area containing the right internal iliac lymph node). One month later, bilateral lung metastases and local penile infiltration appeared; thus, second-line chemotherapy (pembrolizumab) was added to the regimen. The patient rejected further chemotherapy after the first course of pembrolizumab. A computed tomography scan performed four months after one course of pembrolizumab therapy showed complete resolution of the metastatic lesions. As of this writing, 20 months after the first course of pembrolizumab, the patient continues to be in complete remission.
一名78岁男性因肉眼血尿和膀胱肿瘤被转诊至我院,我们最初对其进行了膀胱肿瘤经尿道切除术。病理检查显示肿瘤为高级别浸润性尿路上皮癌,至少为T2期。计算机断层扫描显示膀胱癌无淋巴结或远处转移。考虑行根治性膀胱切除术,我们给予了两个疗程的新辅助化疗(即吉西他滨和顺铂化疗)。不幸的是,膀胱肿瘤转移至右侧髂内淋巴结。我们进行了巩固性放疗(对包含右侧髂内淋巴结的膀胱区域给予54 Gy/27次分割)。1个月后,出现双侧肺转移和局部阴茎浸润;因此,在治疗方案中加入了二线化疗(帕博利珠单抗)。在第一个疗程的帕博利珠单抗治疗后,患者拒绝进一步化疗。在一个疗程的帕博利珠单抗治疗4个月后进行的计算机断层扫描显示转移病灶完全消退。截至撰写本文时,在第一个疗程的帕博利珠单抗治疗20个月后,患者仍处于完全缓解状态。